Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 1, 2018. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a corporate governance notification regarding share capital and voting rights.
| Metric | Value |
|---|---|
| Issued Ordinary Shares (as of Feb 28, 2018) | 5,373,472,560 |
| Share Par Value | 25 pence each |
| Treasury Shares | 414,605,950 |
| Total Voting Rights | 4,958,866,610 |
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period regarding financial performance. The document only states the current capital structure as of February 28, 2018.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements or risk disclosures.
Important Facts for Investors to Verify
- Verify the total number of voting rights (4,958,866,610) to determine notification thresholds under FCA Disclosure Guidance and Transparency Rules.
- Confirm the number of shares held in Treasury (414,605,950) which are excluded from voting rights calculations.
- Note that this filing does not contain financial results; investors should refer to the Company's Form 20-F or quarterly reports for financial data.